Clinical trial
Acarbose Cardiovascular Evaluation Trial
NCT00829660 · University of Oxford, Other · Completed
Key facts
| NCT number | NCT00829660 |
|---|---|
| Title | Acarbose Cardiovascular Evaluation Trial |
| Official title | A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance |
| Acronym | ACE |
| Lead sponsor | University of Oxford, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Heart Disease, Acute Coronary Syndrome, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus (T2DM) |
| Intervention type | Drug |
| Interventions | Acarbose, Matching Placebo |
| Enrollment | 6,526 |
| Start date | Feb 17, 2009 |
| Primary completion | Apr 11, 2017 |
| Completion | Apr 18, 2017 |
| First posted | Jan 27, 2009 |
| Last update posted | Jul 25, 2017 |
| Countries | China, Hong Kong |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: